Shuoxing Bio, Dunen Medicine, and Xinhuang Tech Secure Tens of Millions in RMB Financing to Accelerate High-Quality Transformation and Development

Mar 01, 2024 20:37 CST Updated 20:38

StarMab BioMed

Antibody Drug Developer

StarMab BioMed Completes Tens of Millions in Financing, Focusing on First-in-Class Multi-Functional Antibody Biologics

Recently, Beijing StarMab BioMed Technology Ltd. (referred to as StarMab BioMed) announced the completion of a multi-million RMB A+ round of financing. This round of financing was led byZhuhai Sci-Tech InvestmentZhuhai High-tech Jintou and Guangda Huitong jointly invested, with Qidian Capital serving as the financial advisor for subsequent rounds of financing.

Before this round of financing, StarMab BioMed had already gained favor from well-known institutions in China such as Aethan Capital, CICC Capital, Cowin Capital, and Chang'an Private Capital.

StarMab BioMed, established in 2019, is an innovation-driven biopharmaceutical company dedicated to the discovery and development of novel drugs. Based on its proprietary VHH multi-antibody biologics platform technology, the company focuses on addressing indications with unmet therapeutic needs. It aims to develop innovative multifunctional antibody drugs that are either First-in-Class or Best-in-Class globally, alongside clinical research and commercialization on a global scale.

Its industry-leading VHH antibody discovery platform ensures efficient generation and screening of VHH antibodies to obtain VHH antibody candidates with high affinity and high bioactivity. Its proprietary antibody engineering optimization platform effectively addresses issues related to antibody stability, immunogenicity, half-life, and manufacturability. The uniquely structured VHH multi-antibody molecules exhibit high-affinity targeted binding and synergistic effects; adjustable half-life; mediation of ADCC and ADCP; and possess characteristics such as simple structure, small molecular weight, high expression levels, high purification recovery rates, and excellent stability.

Currently, StarMab BioMed has developed a series of novel biologics with independent intellectual property rights. Several First-in-class multifunctional antibody biologics are undergoing early clinical trials in both China and the United States. Among them, SM3321 has been granted IND approval in both countries and has entered Phase I clinical trials. Preclinical data have demonstrated excellent anti-tumor efficacy and safety. Its unique structural design enables high-affinity targeting and binding to multiple tumor sites while activating immune cell functions, achieving specific killing of tumor cells while minimizing non-specific toxic reactions.

StarMab BioMed's technology in antibody production is also widely recognized in the industry. Using traditional CHO antibody production and purification processes, it can reach industrial-scale production levels.

Recently, StarMab BioMed has obtained the authorization for Lonza's XS® Pichia yeast expression production system, which can greatly simplify the production and purification process of VHH antibodies. While ensuring the bioactivity and yield of the antibodies, it significantly reduces production time and cost.

ShieldMed Completes Tens of Millions of Yuan in A+ Round Financing, Promoting High-Quality Development of Precision Pharmacy Services

Hangzhou Dunen Medical Laboratory Co., Ltd. (hereinafter referred to as "Dunen Medical") recently announced the completion of a multi-million yuan A+ round of financing.

This round of financing was led by Crystal Fund, with other well-known domestic funds participating. The funds will be used for the research and development of precision medication-related products and reagents by Dunen Medical, the continuous enhancement of scientific research service capabilities, and the further market expansion of co-built laboratories.

Shield Medicine is a co-construction unit of the "Clinical Precision Medication Research Center" at Zhejiang Tsinghua Yangtze River Delta Research Institute, and also the technical support and achievement transformation unit of Zhejiang Yangtze River Delta Biomedical Research and Development Center. The company focuses on precision pharmaceutical services, possessing multiple platforms including a clinical personalized medication gene analysis platform, a drug concentration monitoring physicochemical platform, a drug toxicology research platform, and an artificial intelligence prescription assistance system. It also provides clinical testing services, and sells products such as testing equipment and reagent kits centered around precision drug therapy.

Chen Zhijun, founder and chairman of Shieldon Medicine, stated: "Against the backdrop of the current capital market, this round of financing holds significant strategic importance for us. Externally, it represents the capital market's long-term confidence in us. Internally, on one hand, it reflects recognition of Shieldon’s development path and industry value, and on the other hand, it strengthens the company’s confidence and determination to grow. Through this round of financing, we will swiftly complete the transformation of internal and external management as well as our business model. We aim to achieve refined, procedural, and systematic internal management, while externally providing procedural and systematic services, enabling a rapid transition from feasibility to high-quality development."

HeartVoyager Technology Completes Two Rounds of Financing Within Six Months, Global Thinnest 2D Intracardiac Ultrasound Registration Clinical Trial Officially Launched

According to the latest news, Shenzhen XinHuan Technology Co., Ltd. (referred to as "Heart GlobeTechnology")" has officially launched the 7.5F 2D intracardiac echocardiography imaging system (ICE) registration clinical trial, with dozens of clinical enrollments already completed. The size of this ultrasound catheter model is smaller than all ICE products currently on the market globally, approaching the industry's technological limits. It will help minimize complications caused by puncture injuries and provide patients with a high-quality ICE solution made in China.

At the same time, the XinHuan Technology team has taken the lead in developing China's first 4D ICE system, which integrates several cutting-edge ultrasound imaging technologies such as soft beam synthesis and arbitrary waveform transmission, effectively reducing the risks of cardiac interventional procedures and shortening the learning curve for operators.

Based on solid business progress, CardioCore Technology has gained full recognition from investment institutions and completed two rounds of multi-million RMB financing within half a year.

Following the Pre-A round of financing in June 2023, where it raised tens of millions of RMB led by Luxin Venture Capital and co-invested by Zhuhai Beiqing River, CardioCore Technology completed another round of additional financing worth tens of millions of RMB in December 2023. This round was jointly led by a fund under Tongfang Investment and a well-known healthcare fund in the industry, with existing shareholder Zhuhai Beiqing River contributing additional investment. WinX Capital served as the financial advisor for multiple consecutive rounds. The funds raised from this round will be used for product registration clinical trials and the development and iteration of a next-generation product.

In recent years, with the rapid development of percutaneous catheter intervention technology, the diagnosis and treatment in fields such as structural heart disease and arrhythmia have also evolved. As more complex cardiac surgeries are being successfully performed, the requirements for intraoperative imaging are becoming increasingly stringent. In the past, interventional procedures were typically guided by transesophageal echocardiography (TEE), which presented challenges such as patient tolerance and anesthesia coordination. In contrast, intracardiac echocardiography (ICE) offers advantages such as real-time imaging, live monitoring of intraoperative complications, and good patient tolerance (without the need for general anesthesia or deep sedation). ICE has gained clinical consensus and widespread application globally. Multiple clinical studies have shown that ICE can improve the efficacy of atrial fibrillation radiofrequency ablation.、Improving the precision and safety of surgeries such as left atrial appendage closure, reducing the risk of surgical complications, shortening operation time, enhancing patient comfort, and significantly decreasing X-ray usage to lower radiation exposure for both medical staff and patients. With the continuous implementation of bulk procurement across China and the successive release of regulatory policies favorable to domestically produced devices, the interventional ultrasound field, currently dominated by foreign brands, is expected to witness the rise of a group of outstanding Chinese manufacturers.

Editor: Zhu Di